March 2, 2020 / 7:08 PM / a month ago

BRIEF-Samsung Biologics & STCube Enter Development & Manufacturing Agreement​ For ‍STT-003 Antibody​

March 2 (Reuters) - Samsung Biologics Co:

* SAMSUNG BIOLOGICS CO LTD - CO & STCUBE ANNOUNCED A STRATEGIC DEVELOPMENT AND MANUFACTURING SERVICE AGREEMENT FOR STT-003 ANTIBODY

* SAMSUNG BIOLOGICS CO LTD - CO TO OFFER CELL LINE DEVELOPMENT, PROCESS DEVELOPMENT, OTHERS TO IND SUBMISSION FOR STT-003 ANTIBODY

* SAMSUNG BIOLOGICS CO LTD - STCUBE IS PLANNING TO SUBMIT AN IND ON ITS STT-003 ANTIBODY IN 2021 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below